Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia

Tropical Medicine and International Health

Volumn 19, Issue 12, 2014, Pages 1397-1410

  Koole, Olivier ^a,b   Tsui, Sharon ^c,d   Wabwire Mangen, Fred ^e   Kwesigabo, Gideon ^f   Menten, Joris ^b   Mulenga, Modest ^g   Auld, Andrew ^h   Agolory, Simon ^h   Mukadi, Ya Diul ^c   Colebunders, Robert ^b,i   Bangsberg, David R ^j,k   van Praag, Eric ^c   Torpey, Kwasi ^c   Williams, Seymour ^h   Kaplan, Jonathan ^h   Zee, Aaron ^h   Denison, Julie ^c,d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^f MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^g TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

ART; HIV; retention; sub Saharan Africa

Indexed keywords

EFAVIRENZ; EMTRICITABINE; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BODY MASS; DISEASE TREATMENT; DRUG; HAZARD ASSESSMENT; HEALTH POLICY; HUMAN IMMUNODEFICIENCY VIRUS; RISK FACTOR; SYMPTOM;

ADULT; AGE; ANTIRETROVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENDER; HEALTH CARE FACILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMOBILITY; INTERVIEW; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; PATIENT PARTICIPATION; PATIENT RETENTION; RETROSPECTIVE STUDY; RISK FACTOR; TANZANIA; UGANDA; WASTING SYNDROME; WEIGHT REDUCTION; ZAMBIA;

TANZANIA; UGANDA; ZAMBIA;

EID: 85007174677     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12386     Document Type: Article

References (33)

1. Altman DG & Bland JM (1998) Time to event (survival) data. BMJ 317, 468–469.
2. Bangsberg DR, Perry S, Charlebois ED et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15, 1181–1183.
3. Bedelu M, Ford N, Hilderbrand K & Reuter H (2007) Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. Journal of Infectious Diseases 196 (Suppl. 3), S464–S468.
4. Braitstein P, Brinkhof MW, Dabis F et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817–824.
5. Calmy A, Pinoges L, Szumilin E et al. (2006) Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20, 1163–1169.
6. Chan AK, Mateyu G, Jahn A et al. (2010) Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model. Tropical Medicine and International Health 15 (Suppl. 1), 90–97.
7. Coetzee D, Hildebrand K, Boulle A et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887–895.
8. Collet D (2003). Modelling Surival Data in Medical Research, 2nd edn. Chapmann & Hall/CRC Press, Boca Raton, FL, USA.
9. Cornell M, Myer L, Kaplan R, Bekker LG & Wood R (2009) The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Tropical Medicine and International Health 14, 722–731.
10. Cornell M, Grimsrud A, Fairall L et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24, 2263–2270.
11. Decroo T, Telfer B, Biot M et al. (2011) Distribution of antiretroviral treatment through self-forming groups of patients in tete province, mozambique. Journal of Acquired Immune Deficiency Syndromes 56, e39–e44.
12. Ferradini L, Jeannin A, Pinoges L et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367, 1335–1342.
13. Forster M, Bailey C, Brinkhof MW et al. (2008) Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bulletin of the World Health Organization 86, 939–947.
14. Fox MP & Rosen S (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Tropical Medicine and International Health 15 (Suppl. 1), 1–15.
15. Geng EH, Nash D, Kambugu A et al. (2010) Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Current HIV/AIDS Reports 7, 234–244.
16. Giordano TP, Gifford AL, White AC Jr et al. (2007) Retention in care: a challenge to survival with HIV infection. Clinical Infectious Diseases 44, 1493–1499.
17. Hogg RS, Heath K, Bangsberg D et al. (2002) Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16, 1051–1058.
18. Hougaard P (1995) Frailty models for survival data. Lifetime Data Analysis 1, 255–273.
19. Little RJA (1992) Regression with missing X's: a review. Journal of the American Statistical Association 87, 1227–1237.
20. May M, Boulle A, Phiri S et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376, 449–457.
21. MSF and UNAIDS (2012). Closer to Home: Delivering Antiretroviral Therapy in the Community: Experience From Four Countries in Southern Africa. MSF and UNAIDS, Geneva, Switzerland.
22. Nachega JB, Hislop M, Dowdy DW et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Annals of Internal Medicine 146, 564–573.
23. Paterson DL, Swindells S, Mohr J et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133, 21–30.
24. Pocock SJ, Clayton TC & Altman DG (2002) Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359, 1686–1689.
25. Rich ML, Miller AC, Niyigena P et al. (2012) Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. Journal of Acquired Immune Deficiency Syndromes 59, e35–e42.
26. Rosen S, Fox MP & Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Medicine 4, e298.
27. Royston P (2004) Multiple imputation of missing values. Stata Journal 4, 227–241.
28. Shepherd BE, Blevins M, Vaz LM et al. (2013) Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. American Journal of Epidemiology 178, 819–828.
29. UNAIDS (2014). The Gap Report. UNAIDS, Geneva, Switzerland.
30. Weigel R, Estill J, Egger M et al. (2012) Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 26, 365–373.
31. WHO (2006). Patient Monitoring Guidelines for HIV Care and ART. WHO, Geneva, Switzerland.
32. WHO (2013). Consolidated Guidelines on the Use Of Antiretroviral Drugs For Treating and Preventing HIV Infection. Recommendations for a Public Health Approach 2013. WHO, Geneva, Switzerland.
33. Wools-Kaloustian KK, Sidle JE, Selke HM et al. (2009) A model for extending antiretroviral care beyond the rural health centre. Journal of the International AIDS Society 12, 12–22.